China Aoxing Pharmaceutical today reported year-end results to June 30 with revenues up 27 percent to US$8,941,907 and gross profit up 18 percent to US$3,806,246.
The company attributes the increase to increased marketing efforts, improved brand recognition and effective pricing strategy.
The company also invested more in research and development, raising its spend from US$700,202 in fiscal year 2008 to US$722,567 in fiscal year 2009. Development programs include Oxycodone, Tilidine, Codeine Phosphate and Buprenorphine.